The UK and US have concluded a major bilateral deal that will keep zero import taxes on UK drug shipments going into the American market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has agreed to increase funding on drugs through the public health system. This commitment secures that import taxes on these key goods will remain at nothing for a duration of the next three years.
This agreement comes after previous threats to significantly raise tariffs on branded drug imports, with figures mentioned reaching one hundred percent.
"This arrangement between the United Kingdom bolsters the global environment for innovative medicines and introduces long-overdue fairness to American-British medicine commerce," a statement declared.
Trade Impact
Drugs constitute one of the UK's most significant export categories to the United States, which is by far the largest destination for large companies like GSK and AstraZeneca.
Statistics show that in the 12 months leading up to the third quarter, the UK shipped drugs totaling £11.1bn to the US. This amount made up a significant portion of total UK exports in that timeframe.
"This agreement secures jobs, stimulates capital expenditure and sets the stage for the UK to become a international leader for life sciences," the Business and Trade Secretary remarked.
Specific British Pledges
The pact involves several notable commitments from the United Kingdom:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it judges new medicines to be unaffordable by 25%.
- Higher Drug Budget: There is a goal to increase total health service expenditure on treatments from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage drug companies must refund to the NHS to stay within budget will be limited at 15%. Previously, rebates topped 20%.
Recent Tensions
The deal comes amid a protracted tension between the sector and the British authorities over spending levels and NHS adoption.
This friction were exacerbated by claims that US patients were paying significantly more for the identical medicines than patients in the UK and Europe.
Recently, several major pharmaceutical investments in the UK have been paused or cancelled, while major investments have been directed toward American operations.
The Science Minister acknowledged that the NHS needed to invest a greater share on treatments, noting that its budget allocation on drugs had decreased as a proportion of its resources over the previous ten-year period.
